WASHINGTON - After percolating for months, the biogeneric debate spilled out on Capitol Hill Thursday at a hearing of the Senate Health, Education, Labor and Pensions Committee, and its overall tone seemed to favor pioneer drugmakers. (BioWorld Today)

WASHINGTON - After percolating for months, the biogeneric debate spilled out on Capitol Hill Thursday at a hearing of the Senate Health, Education, Labor and Pensions Committee, and its overall tone seemed to favor pioneer drugmakers. (BioWorld Today)

The FDA approved a new drug for high blood pressure, Tekturna (aliskiren), a first-in-class product partnered between Speedel Group and Novartis AG. (BioWorld Today)